Search Results

Your search for Dung T. Le, MD matches 2 pages

Showing 1 - 2

By Dung T. Le, MD / 2016 Gastrointestinal Cancers Symposium

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).

colorectal cancer

solid tumors

gynecologic cancers

By The ASCO Post Staff / Friday, May 29, 2015 4:25 PM

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

A phase II study identified the first genomic marker—mismatch repair deficiency—to predict clinical benefit of immune checkpoint blockade with the anti–PD-1 antibody pembrolizumab (Keytruda). Among 50 patients with colorectal cancer, 62% of the 25 patients with mismatch...

Apr

Today In Oncology

Search Results

Your search for Dung T. Le, MD matches 2 pages

Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

ASCO 2015: Mismatch Repair Deficiency Predicts Response to Pembrolizumab Among Patients With Colorectal and Other Cancers

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer